Victoria Federico Paly

Victoria Federico Paly

Auto-generated profile, based on publicly available information

Victoria Federico Paly

Takeda Pharmaceuticals America, Inc., Cambridge, MA 02142, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2013 in BMC Medical Imaging
Verified
Journal Article
Open access
PDF file
KLKathleen Lang
Kathleen Lang
HHHuan Huang
Huan Huang
DLDavid W Lee
David W Lee
VFVictoria Federico
Victoria Federico
JMJoseph Menzin
Joseph Menzin
Background: Concerns have been raised regarding growth in advanced diagnostic imaging use. This study evaluated trends in national outpatient MRI/CT utilization rates during 2000-2009 and factors associated with utilization. Methods: This retrospective database analysis used data on all respondents in the nationally representative U.S. Medical Expenditure Panel Survey (MEPS) during 2000-2009. Visits involving advanced diagnostic imaging were identified based on self-reported use of MRI or CT tests at emergency departments, office-based medical providers, and outpatient departments. The imaging utilization rate was defined as the number of outpatient visits with MRI/CT per 1,000 person-years. Results were weighted to create nationally representative estimates at the person-year level for each year and the pooled 10-year period. A multivariate logistic regression was estimated to identify predictors of imaging use. Results: A total of 319,246 person-years were included in the analysis. MRI/CT utilization rates increased from 64.3 to 109.1 per 1,000 person years from 2000 to 2009, with older persons, females and Medicare enrollees having higher rates of use. Growth in imaging slowed in recent years; the average annual decline in the imaging growth rate was larger than that for all outpatient services (4.7% vs. 0.9%). The percentage of respondents with MRI/CT use (6.7% during 2000-2009) also increased at a slower rate in later years and declined during 2007-2009. The average number of MRI/CT visits among imaging users was steady at about 1.5 visits during 2000-2009. Age, female gender, White race, HMO participation, and all payer types (vs. uninsured) were significant predictors of imaging use. Compared to 2005, years 2000-2003 were associated with a significantly lower likelihood of imaging use, while years 2004-2009 were not significantly associated, suggesting a slow-down in later years. Conclusions: Growth in advanced imaging utilization appears to have slowed in recent years, a finding of potential interest to policy-makers and payers.

5 June 2014 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MZMarya D Zilberberg
Marya D Zilberberg
ASAndrew F. Shorr
Andrew F. Shorr
HHHuan Huang
Huan Huang
PCParesh Chaudhari
Paresh Chaudhari
VPVictoria Federico Paly
Victoria Federico Paly
JMJoseph Menzin
Joseph Menzin
Mucormycosis is a rare and potentially fatal fungal infection occurring primarily in severely immunosuppressed patients. Because it is so rare, reports in the literature are mainly limited to case reports or small case series. The aim of this study was to evaluate inpatient mortality, length of stay (LOS), and costs among a matched sample of high-risk patients with and without mucormycosis in a large nationally representative database.

25 June 2012 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
JMJoseph Menzin
Joseph Menzin
JMJeno P Marton
Jeno P Marton
JMJordan A Menzin
Jordan A Menzin
RWRichard J Willke
Richard J Willke
RWRebecca M Woodward
Rebecca M Woodward
VFVictoria Federico
Victoria Federico
Researchers and policy makers have determined that accounting for productivity costs, or “indirect costs,” may be as important as including direct medical expenditures when evaluating the societal value of health interventions. These costs are also important when estimating the global burden of disease. The estimation of indirect costs is commonly done on a country-specific basis. However, there are few studies that evaluate indirect costs across countries using a consistent methodology.

31 July 2014 in The Patient - Patient-Centered Outcomes Research
Verified
Journal Article
Closed access
PDF file
JBJohn F. P. Bridges
John F. P. Bridges
VPVictoria Federico Paly
Victoria Federico Paly
EBElizabeth Barker
Elizabeth Barker
DKDolly Kervitsky
Dolly Kervitsky

1 January 2022 in MDM Policy & Practice
Verified
Journal Article
Open access
VPVictoria Federico Paly
Victoria Federico Paly
MKMurat Kurt
Murat Kurt
LZLirong Zhang
Lirong Zhang
MBMarcus O. Butler
Marcus O. Butler
OMOlivier Michielin
Olivier Michielin
JBJohn Borrill
John Borrill
Background: Survival heterogeneity and limited trial follow-up present challenges for estimating lifetime benefits of oncology therapies. This study used CheckMate 067 (NCT01844505) extended follow-up data to assess the predictive accuracy of standard parametric and flexible models in estimating the long-term overall survival benefit of nivolumab plus ipilimumab (an immune checkpoint inhibitor combination) in advanced melanoma. Methods: Six sets of survival models (standard parametric, piecewise, cubic spline, mixture cure, parametric mixture, and landmark response models) were independently fitted to overall survival data for treatments in CheckMate 067 (nivolumab plus ipilimumab, nivolumab, and ipilimumab) using successive data cuts (28, 40, 52, and 60 mo). Standard parametric models allow survival extrapolation in the absence of a complex hazard. Piecewise and cubic spline models allow additional flexibility in fitting the hazard function. Mixture cure, parametric mixture, and landmark response models provide flexibility by explicitly incorporating survival heterogeneity. Sixty-month follow-up data, external ipilimumab data, and clinical expert opinion were used to evaluate model estimation accuracy. Lifetime survival projections were compared using a 5% discount rate. Results: Standard parametric, piecewise, and cubic spline models underestimated overall survival at 60 mo for the 28-mo data cut. Compared with other models, mixture cure, parametric mixture, and landmark response models provided more accurate long-term overall survival estimates versus external data, higher mean survival benefit over 20 y for the 28-mo data cut, and more consistent 20-y mean overall survival estimates across data cuts. Conclusion: This case study demonstrates that survival models explicitly incorporating survival heterogeneity showed greater accuracy for early data cuts than standard parametric models did, consistent with similar immune checkpoint inhibitor survival validation studies in advanced melanoma. Research is required to assess generalizability to other tumors and disease stages. Highlights: Given that short clinical trial follow-up periods and survival heterogeneity introduce uncertainty in the health technology assessment of oncology therapies, this study evaluated the suitability of conventional parametric survival modeling approaches as compared with more flexible models in the context of immune checkpoint inhibitors that have the potential to provide lasting survival benefits. This study used extended follow-up data from the phase III CheckMate 067 trial (NCT01844505) to assess the predictive accuracy of standard parametric models in comparison with more flexible methods for estimating the long-term survival benefit of the immune checkpoint inhibitor combination of nivolumab plus ipilimumab in advanced melanoma. Mixture cure, parametric mixture, and landmark response models provided more accurate estimates of long-term overall survival versus external data than other models tested. In this case study with immune checkpoint inhibitor therapies in advanced melanoma, extrapolation models that explicitly incorporate differences in cancer survival between observed or latent subgroups showed greater accuracy with both early and later data cuts than other approaches did.

28 October 2020 in Journal of Medical Economics
Verified
Journal Article
Open access
VPVictoria Federico Paly
Victoria Federico Paly
YHYusuke Hikichi
Yusuke Hikichi
TBTimothy Baker
Timothy Baker
EIEijun Itakura
Eijun Itakura
NCNisha Chandran
Nisha Chandran
JHJames Harrison
James Harrison
The objective of this study was to evaluate the cost-effectiveness of nivolumab in combination with ipilimumab (nivo + ipi) compared to current therapeutic alternatives in first-line treatment of p...